Sun Pharmaceutical Industries (SUNPHARMA) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE044A01036
Key metrics
- Market Cap
- ₹4.22 L Cr
- P/E Ratio
- 34.93
- EPS
- 50.4
- Book Value
- 349.6
- P/B Ratio
- 5.04
- ROE
- 13.69%
- ROCE
- 15.36%
- Debt / Equity
- 0.06
- Net Margin
- 19.72%
- Revenue Growth
- 11.87%
- Profit Growth
- 5.04%
- Dividend Yield
- 0.91%
- 52W High
- ₹2,046.90
- 52W Low
- ₹1,583.70
- Market Cap Band
- large cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 47,000
- Promoter Holding
- 55.61%
Sun Pharmaceutical Industries and the Drug Manufacturers - Specialty & Generic industry
Sun Pharmaceutical Industries is one of 153 listed companies in the Drug Manufacturers - Specialty & Generic industry. At a P/E of 34.9, it trades above the industry median of 30.6.
All Drug Manufacturers - Specialty & Generic stocks →Healthcare sector stocks →
Related companies
- Divi's LaboratoriesDIVISLAB · ₹9,087.00₹2.43 L Cr
- Torrent PharmaceuticalsTORNTPHARM · ₹4,558.70₹1.74 L Cr
- Zydus LifesciencesZYDUSLIFE · ₹1,113.90₹1.12 L Cr
- Laurus LabsLAURUSLABS · ₹2,069.00₹1.11 L Cr
- CiplaCIPLA · ₹1,324.10₹1.07 L Cr
- Dr. Reddy's LaboratoriesDRREDDY · ₹1,242.50₹1.03 L Cr
- Aurobindo PharmaAUROPHARMA · ₹1,621.40₹95,910 Cr
- Mankind PharmaMANKIND · ₹2,253.20₹93,988 Cr
Sun Pharmaceutical Industries: key questions
What does Sun Pharmaceutical Industries do?
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally.
What is the share price of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries (SUNPHARMA) last traded at ₹1,743.00 on the NSE, down 0.9% on the day. Over the past 52 weeks it has traded between ₹1,583.70 and ₹2,046.90. The current price is 14.8% below its 52-week high.
What is the market cap of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a market capitalisation of ₹4.22 L Cr, which makes it a large-cap company. It is the 1st largest of 153 listed companies in the Drug Manufacturers - Specialty & Generic industry by market capitalisation.
What is the P/E ratio of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries trades at a price-to-earnings (P/E) ratio of 34.9. The median P/E across profitable companies in the Drug Manufacturers - Specialty & Generic industry is 30.6.
What are Sun Pharmaceutical Industries's ROE and ROCE?
For the financial year ended March 2026, Sun Pharmaceutical Industries reported a return on equity (ROE) of 13.7%, a return on capital employed (ROCE) of 15.4% and a net profit margin of 19.7%.
How fast is Sun Pharmaceutical Industries growing?
In the financial year ended March 2026, Sun Pharmaceutical Industries's revenue grew 11.9% and net profit grew 5.0% compared with the previous year.
Does Sun Pharmaceutical Industries have debt?
Sun Pharmaceutical Industries has a debt-to-equity ratio of 0.06, meaning borrowings are about 6% of shareholders' equity.
Does Sun Pharmaceutical Industries pay a dividend?
Sun Pharmaceutical Industries has a dividend yield of 0.91% at the current share price.
What is the promoter holding in Sun Pharmaceutical Industries?
Promoters hold 55.6% of Sun Pharmaceutical Industries. Institutional investors hold 29.2%.
Which companies are similar to Sun Pharmaceutical Industries?
Listed companies close to Sun Pharmaceutical Industries in size within the Drug Manufacturers - Specialty & Generic industry include Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Laurus Labs, Cipla and Dr. Reddy's Laboratories.
Figures are for information only and are not investment advice.
The full Sun Pharmaceutical Industries analysis
Create a free account to open the complete SUNPHARMA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.